New antibiotics to overcome antibacterial resistance presented at ECCMID

12 April 2016
2019_biotech_test_vial_discovery_big

Antimicrobial drug pipelines have been presented the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

Small and innovative companies, with products in early stages of development, shared some of their novel approaches and antimicrobial therapies during a dedicated session at the event in Amsterdam.

Some of these emerging biotech companies and start-ups are filling the gap left by big pharma’s continuing move away from the development of antibacterial treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology